Yasmin Rahim

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates

Karim Fizazi, Allan Lipton, Xavier Mariette et al. · Journal of Clinical Oncology · 2009 · 534 citations

Medicine, Oncology, Pharmacology +17

Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial

Monika K. Krzyzanowska, Jim A. Julian, Chu‐Shu Gu et al. · BMJ · 2021 · 48 citations · Full text

Medicine, Oncology, Breast Oncology +16

Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines

Maureen Trudeau, Mark Clemons, Louise Provencher et al. · Journal of Clinical Oncology · 2009 · 37 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer

Srikala S. Sridhar, Normand Blais, Ben Tran et al. · JAMA Oncology · 2020 · 36 citations · Full text

Medicine, Oncology, Pharmacotherapy +15